Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
20 Febbraio 2024 - 2:00PM
Business Wire
The virtual event will take place on Monday,
February 26th, 2024, at 4:30PM ET
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced it
will host a virtual event discussing updated clinical data for
PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February
26th, 2024, at 4:30PM ET.
David Campbell, Ph.D., President & Chief Executive Officer
will discuss interim clinical updates for JANX007, a TRACTr that
targets prostate-specific membrane antigen (PSMA) and is being
investigated in a Phase 1 dose escalation clinical trial in adult
subjects with metastatic castration-resistant prostate cancer
(mCRPC) and JANX008, a TRACTr that targets epidermal growth factor
receptor (EGFR) and is being investigated in a Phase 1 dose
escalation clinical trial in adult subjects with non-small cell
lung cancer, renal cell carcinoma, colorectal cancer, and squamous
cell carcinoma of the head and neck. Specifically, the company will
provide clinical efficacy and safety updates to report on progress
towards identifying doses for expansion studies with JANX007, and
on early dose escalation data for JANX008.
The company anticipates providing an update on identifying doses
to be evaluated in expansion cohorts for JANX007 in 2H 2024.
A live question and answer session will follow the formal
presentation. To register for the event, please click here.
Janux’s TRACTr and TRACIr Pipeline
Janux’s first clinical candidate, JANX007, is a TRACTr that
targets PSMA and is being investigated in a Phase 1 clinical trial
in adult subjects with mCRPC. Janux’s second clinical candidate,
JANX008, is a TRACTr that targets EGFR and is being studied in a
Phase 1 clinical trial for the treatment of multiple solid cancers
including non-small cell lung cancer, renal cell carcinoma,
colorectal cancer, and squamous cell carcinoma of the head and
neck. Janux is also applying its proprietary technology to develop
a TRACTr designed to target TROP2, a clinically validated
anti-tumor target that is overexpressed in various cancer types,
such as breast, lung, urothelial, endometrial, ovarian, prostate,
pancreatic, gastric, colon, head and neck, and glioma. Janux’s
TRACIr drug candidate, JANX009, is designed for targeting both the
programmed death-ligand 1 (PD-L1) receptor as well as the
costimulatory CD28 receptor on T cells for the treatment of solid
tumors. In addition to named programs, Janux is generating a number
of unnamed TRACTr and TRACIr programs for potential future
development.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing
tumor-activated immunotherapies for cancer. Janux’s proprietary
technology enabled the development of two distinct bispecific
platforms: TRACTr and TRACIr. The goal of both platforms is to
provide cancer patients with safe and effective therapeutics that
direct and guide their immune system to eradicate tumors while
minimizing safety concerns. Janux is currently developing a broad
pipeline of TRACTr and TRACIr therapeutics directed at several
targets to treat solid tumors. Janux has two TRACTr therapeutic
candidates in clinical trials, the first targeting PSMA is in
development for prostate cancer, and the second targeting EGFR is
being developed for colorectal, lung, head and neck, and renal
cancers. For more information, please visit www.januxrx.com and
follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, Janux’s ability to bring new
treatments to cancer patients in need and expectations regarding
the timing, scope and results of Janux’s development activities.
Factors that may cause actual results to differ materially include
the risk that compounds that appear promising in early research do
not demonstrate safety and/or efficacy in later preclinical studies
or clinical trials, the risk that Janux may not obtain approval to
market its product candidates, uncertainties associated with
performing clinical trials, regulatory filings and applications,
risks associated with reliance on third parties to successfully
conduct clinical trials, the risks associated with reliance on
outside financing to meet capital requirements, and other risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. You are urged to consider statements that include the
words “may,” “will,” “would,” “could,” “should,” “believes,”
“estimates,” “projects,” “promise,” “potential,” “expects,”
“plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,”
or the negative of those words or other comparable words to be
uncertain and forward-looking. For a further list and description
of the risks and uncertainties Janux faces, please refer to Janux’s
periodic and other filings with the Securities and Exchange
Commission, which are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and Janux assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220601963/en/
Investors: Andy Meyer Janux Therapeutics
ameyer@januxrx.com (202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications
Inc. jessica@litldog.com (858) 344-8091
Grafico Azioni Janux Therapeutics (NASDAQ:JANX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Janux Therapeutics (NASDAQ:JANX)
Storico
Da Set 2023 a Set 2024